Agenda

CONFERENCE DAY 1
Thursday, 11 October 2018
CONFERENCE DAY 2
Friday, 12 October 2018

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Keynote: Future of Pharma

Keynote: Innovation from Europe for Europe – Breaking the Vicious Cycles of Eye Disease with a New Turn

Presented by Novaliq

Presented by Novaliq

Networking & Refreshments in Exhibition Hall

Physicians Panel

Presented by Lifescience Dynamics

Presented by Lifescience Dynamics

Keynote Panel: Reaction/Response to Keynote Presentations

Presented by Actelion, Johnson & Johnson, Elanco, GlaxoSmithKline, H. Lundbeck A/S, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Presented by Actelion, Johnson & Johnson, Elanco, GlaxoSmithKline, H. Lundbeck A/S, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Networking Luncheon

SESSION ONE

Orphan Drugs: A Way to Evaluate Pharmaceutical Products for Rare Diseases

In the last twenty years there has been a larger focus on addressing the unmet treatment needs for rare diseases.

Many pharmaceutical companies are trying to develop drugs for different rare and ultra-rare diseases. To advance product to the next stage of clinical or commercial development, which will be require significant investments, pharma companies aim to make decisions based on projected financial performance of the product by using NPV and ROI analysis. One of most important and most challenging steps in financial valuation is understanding the commercial potentials of the product. Indeed, product forecast is viewed as the most crucial and inevitable part of the valuation process.

This presentation will focus on the unique challenges that rare diseases pose for assessment and forecasting of orphan drugs, different tools to overcome the challenges faced by industry when identifying relevant data sources to evaluate orphan products, outline strengths and limitations of available methods as well as what could be done differently to help improve outcomes.

Presented by Mallinckrodt Pharmaceuticals

Presented by Mallinckrodt Pharmaceuticals

SESSION TWO

Everything You Always Wanted to Know About Innovation in Market Research (But Were Afraid to Ask)

Presented by Bayer

Presented by Bayer

SESSION ONE

Navigating Fear and Secrecy: Researching Solutions to the Problem of Food Insecurity

Food insecurity affects nearly one in five residents of Philadelphia.

And yet, programs offering help have a surprisingly low participation rate. At-risk families fear not only hunger, but losing custody of children if their situation is discovered. This case study explores research strategies designed to overcome fear and secrecy in order to assess potential interventions.

Presented by M Health

Presented by M Health

SESSION TWO

The Doctor Will See You Now

AplusA initiated a research in the UK and in France to understand current and future challenges faced by the primary

care community, including those pertaining to digital healthcare platforms and their expected impact on their profession, both positive and negative.

Presented by AplusA

Presented by AplusA

SESSION ONE

How to Position a New Anesthetic/Sedative in Market Research

Presented by PAION AG

Presented by PAION AG

SESSION TWO

Title TBA

Presented by Lifescience Dynamics

Presented by Lifescience Dynamics

Networking & Refreshments in Exhibition Hall

SESSION ONE

Predictive Modeling – The Future of Tracking

Tracking research is one of the cornerstones of pharmaceutical research, but too often the findings fail to be used to their fullest extent – to inform clients where to act, and what the impact of action is likely to be.

This paper proposes a predictive modelling and advanced analytics framework, leveraging machine learning and automation principles to assess past trends (tracking results) and deliver forward-looking insight at scale. The result is enhanced understanding, and the ability for sales and marketing teams to identify which actions will have the greatest impact on brand performance, leading to more actionable brand management.

Presented by Cello Health Insight

Presented by Cello Health Insight

SESSION TWO

Title TBA

Presented by Research Partnership

Presented by Research Partnership

SESSION ONE

Measurement of Business Impact of Insights

Presented by Actelion, Boehringer Ingelheim, Jazz Pharmaceuticals, and Orthogen

Presented by Actelion, Boehringer Ingelheim, Jazz Pharmaceuticals, and Orthogen

SESSION TWO

Hunting Consumer Insight: Approaches and Techniques

Presented by Nano Repro, Jazz Pharmaceuticals, and Virbac

Presented by Nano Repro, Jazz Pharmaceuticals, and Virbac

Evening Socializing & Networking Reception in Exhibition Hall

Registration & Networking Breakfast in Exhibition Hall

SESSION ONE

Big Data – Real Time Targeted Insights

Presented by Sanofi

Presented by Sanofi

SESSION TWO

Market Insights and Forecasting for Cell and Gene Therapies, a Manufacturer’s Perspective

Cell and Gene Therapies are seen as the next frontier in medicine, they have the potential to bring potential cures to patients that suffer from life-threatening diseases without many treatment options available.

The idea that a patient’s own cells can be reprogrammed to attack cancer cells or viruses can be used to repair faulty genes is a paradigm shift in medicine. However, a key challenge for all players and drug-makers in this field remains: significant cost of manufacturing, high price tags and the uncertainty around the market acceptance and uptake make it hard to forecast the potential of these innovative therapies. In this presentation, Fatma Aybegum Senkesen will introduce the audience to the basics of the science behind these therapies and also review how both conventional and innovative methods can be utilized to project the future of this innovative market.

Presented by Lonza

Presented by Lonza

SESSION ONE

Uncovering the Unspoken: The Power of Implicit Methods to Capture the Needs of Both Patients and Doctors and Optimize User Experience

Presented by eye square

Presented by eye square

SESSION TWO

Title TBA

Presented by SKIM

Presented by SKIM

SESSION ONE

Title TBA

SESSION TWO

Patient Centricity in Market Research: From Aspiration to Reality

Presented by UCB

Presented by UCB

Networking & Refreshments in Exhibition Hall

Networking Round Tables Session 1

ROUND TABLE 1
Behavioral Economics Applications to Market Research
Presented by Ferring Pharmaceuticals

Presented by Ferring Pharmaceuticals

ROUND TABLE 2
Competitive Intelligence by Market: How to Tailor and Adjust Your Expansion Strategy
Presented by Nano Repro

Presented by Nano Repro

ROUND TABLE 3
Sample and Survey vs Search and Scrape

Consumer market research is moving to gain more and more insights from consumer activity on the internet (not withstanding GDPR and Cambridge Analytical).

Is pharma is different? Can we gain insights into patients and physician from the internet? Are they a representative sample who can we answers our key business questions?

Presented by Boehringer Ingelheim

Presented by Boehringer Ingelheim

Networking Round Tables Session 2

ROUND TABLE 4
What is the Best Data Strategy to Respond to the Increasing Need for Faster and Cheaper Customer Insights? How to Get Organizations to Recognize the Value of and Acting Upon Such Strategy
Presented by GlaxoSmithKline

Presented by GlaxoSmithKline

ROUND TABLE 5
Omnichannel Marketing (How to Do It, How Not to Do It, and How to Measure If It Works)
Presented by Fujirebio

Presented by Fujirebio

ROUND TABLE 6
Title TBA
Presented by Gilead

Presented by Gilead

Networking Luncheon

Announcement of Raffle Prize Winners

Summary & Key Takeaways

Presented by Actelion, Johnson & Johnson, Elanco, GlaxoSmithKline, H. Lundbeck A/S, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Presented by Actelion, Johnson & Johnson, Elanco, GlaxoSmithKline, H. Lundbeck A/S, Merz Pharmaceuticals GmbH, MSD, Teva Pharmaceuticals, and UCB

Conference Concludes